Trial · NCT03280030
Adverse events1,183
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 1,183
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | Placebo: Part 2 (Post-treatment Survival Follow-up) | 0 | ||
| other | Neutropenia | Blood and lymphatic system disorders | Other Participants | 0 | ||
| other | Pancytopenia | Blood and lymphatic system disorders | Midostaurin: Part 1 (Japan Only) (On-treatment) | 2 | 5 | |
| other | Pancytopenia | Blood and lymphatic system disorders | Midostaurin: Part 2 (On-treatment) | 1 | 30 | |
| other | Pancytopenia | Blood and lymphatic system disorders | Placebo Part 2 (On-treatment) | 0 | 31 | |
| other | Pancytopenia | Blood and lymphatic system disorders | Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | 0 | ||
| other | Pancytopenia | Blood and lymphatic system disorders | Midostaurin: Part 2 (Post-treatment Survival Follow-up) | 0 | ||
| other | Pancytopenia | Blood and lymphatic system disorders | Placebo: Part 2 (Post-treatment Survival Follow-up) | 0 | ||
| other | Pancytopenia | Blood and lymphatic system disorders | Other Participants | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Midostaurin: Part 1 (Japan Only) (On-treatment) | 0 | 5 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Midostaurin: Part 2 (On-treatment) | 10 | 30 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo Part 2 (On-treatment) | 3 | 31 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Midostaurin: Part 2 (Post-treatment Survival Follow-up) | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo: Part 2 (Post-treatment Survival Follow-up) | 0 | ||
| other | Thrombocytopenia | Blood and lymphatic system disorders | Other Participants | 0 | ||
| other | Cardiac failure | Cardiac disorders | Midostaurin: Part 1 (Japan Only) (On-treatment) | 1 | 5 | |
| other | Cardiac failure | Cardiac disorders | Midostaurin: Part 2 (On-treatment) | 1 | 30 | |
| other | Cardiac failure | Cardiac disorders | Placebo Part 2 (On-treatment) | 0 | 31 | |
| other | Cardiac failure | Cardiac disorders | Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03280030/events?page=3